Results 291 to 300 of about 16,343,665 (315)

Are Boot Camps an Effective Teaching Modality for Junior Otolaryngology Residents?

The Laryngoscope, EarlyView.
Christopher J. Chin, Kevin Fung, Maya G. Sardesai, Peng You, Kathryn Roth   +4 more
wiley   +1 more source

GSK-3: a multifaceted player in acute leukemias

Leukemia, 2021
Glycogen synthase kinase 3 (GSK-3) consists of two isoforms (α and β) that were originally linked to glucose metabolism regulation. However, GSK-3 is also involved in several signaling pathways controlling many different key functions in healthy cells.
A. Martelli, C. Evangelisti, F. Paganelli, F. Chiarini, J. McCubrey   +4 more
semanticscholar   +7 more sources

Cdc42 & GSK-3: signals at the crossroads [PDF]

Nature Cell Biology, 2003
Cell polarity is regulated by independent pathways that are controlled by Wnt- or Cdc42-mediated signalling. Now, glycogen synthase kinase 3 (GSK-3), an established component of the Wnt pathway, is shown to interact with Par6–protein kinase C ζ (PKCζ), a complex that transduces Cdc42 signals.
Adrian J. Harwood, Vania M.M. Braga
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Schizophrenia as a GSK-3 dysregulation disorder

Trends in Neurosciences, 2007
Converging evidence suggests that the regulation of glycogen synthase kinase 3 (GSK-3) might be important in schizophrenia. Atypical and typical antipsychotic drugs alter GSK-3 activity, as do drugs that induce psychosis. GSK-3 regulatory pathways are altered in schizophrenia, and many of the genes associated with schizophrenia directly or indirectly ...
Lovestone, S, Killick, R, Di Forti, M, Murray, R   +3 more
openaire   +4 more sources

GSK-3 Inhibitors: Discoveries and Developments

Current Medicinal Chemistry, 2004
Glycogen synthase kinase 3 (GSK-3) in the 21(st) century emerged as one of the most attractive therapeutic target for the development of selective inhibitors as new promising drugs for unmet pathologies including Alzheimer's disease, stroke, bipolar disorders, chronic inflammatory processes, cancer and diabetes type II.
Ana Martínez, Mercedes Alonso
openaire   +3 more sources

GSK-3 and the neurodevelopmental hypothesis of schizophrenia

European Neuropsychopharmacology, 2002
The Neurodevelopmental Hypothesis of schizophrenia suggests that interaction between genetic and environmental events occurring during critical early periods in neuronal growth may negatively influence the way by which nerve cells are laid down, differentiated and selectively culled by apoptosis.
Robert H. Belmaker, Robert H. Belmaker, Galila Agam, Nitsan Kozlovsky   +3 more
openaire   +2 more sources

Anti-inflammatory Potential of GSK-3 Inhibitors

Current Drug Targets, 2021
Glycogen synthase kinase-3 (GSK-3) is a protein kinase containing threonine or serine amino acid residues. GSK-3 was first discovered in 1980 as a regulatory protein kinase, Glycogen synthase (GS) enzyme, which is responsible for the conversion of glycogen from glucose with the help of uridine diphosphate glucose (UDP-Glu) residue.
Chandi C. Kandar, Debanjan Sen, Arindam Maity   +2 more
openaire   +2 more sources

Effects and mechanism of epigallocatechin-3-gallate on apoptosis and mTOR/AKT/GSK-3&bgr; pathway in substantia nigra neurons in Parkinson rats

NeuroReport, 2019
The aim of this study is to investigate the protective effect of epigallocatechin-3-gallate (EGCG) on apoptosis and mTOR/AKT/GSK-3&bgr; pathway in substantia nigra neurons in 6-dopamine-induced Parkinson rats.
W. Zhou, Lei Chen, Xiqing Hu, Shanshan Cao, Junxiu Yang   +4 more
semanticscholar   +1 more source

Effect of GSK-3 overactivation on neurofilament phosphorylation

Journal of Huazhong University of Science and Technology [Medical Sciences], 2005
In this study, we studied the effect of glycogen synthase kinase-3 (GSK-3) overactivation on neurofilament phosphorylation in cultured cells. After N2a cells were treated with the specific inhibitor (wortmannin) of phosphoinositol-3 kinase (PI-3K) or treated with wortmannin and the specific inhibitor (LiCl) of glycogen synthase kinase-3 (GSK-3), GSK-3 ...
Youmei Feng, Jie Zhou, Jian-Zhi Wang, Juan Chen   +3 more
openaire   +2 more sources

Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of β-TrCP and GSK-3.

Biochemical Society Transactions, 2015
UNLABELLED Nuclear factor-erythroid 2 p45 (NF-E2 p45)-related factor 2 (Nrf2) is a master regulator of redox homoeostasis that allows cells to adapt to oxidative stress and also promotes cell proliferation.
J. Hayes, S. Chowdhry, A. Dinkova-Kostova, C. Sutherland   +3 more
semanticscholar   +1 more source